Tokyo Tape
Sign in
← Taiko Pharmaceutical

Quarterly report · Q2

4574.TEDINET S100RMXK
Period2023-01-01 → 2023-06-30
Filed2023-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥2.5bn2023-01-01 → 2023-06-30Cons.Net sales
Revenue¥5.0bn2022-01-01 → 2022-12-31Cons.Net sales (5-year summary)
Revenue¥1.9bn2022-01-01 → 2022-06-30Cons.Net sales
Operating income−¥396m2023-01-01 → 2023-06-30Cons.Operating income
Operating income−¥2.4bn2022-01-01 → 2022-06-30Cons.Operating income
Ordinary income−¥510m2023-01-01 → 2023-06-30Cons.Ordinary income
Ordinary income−¥3.4bn2022-01-01 → 2022-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥2.5bn2022-01-01 → 2022-06-30Cons.Ordinary income
Profit before tax−¥492m2023-01-01 → 2023-06-30Cons.Income before income taxes
Profit before tax−¥2.8bn2022-01-01 → 2022-06-30Cons.Income before income taxes
Net income (owners)−¥514m2023-01-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥4.9bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥2.8bn2022-01-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income−¥514m2023-01-01 → 2023-06-30Cons.Profit loss
Net income−¥2.8bn2022-01-01 → 2022-06-30Cons.Profit loss
Total assets¥15.6bnat 2023-06-30Cons.Assets
Total assets¥15.0bnat 2022-12-31Cons.Assets
Total assets¥17.4bnat 2022-06-30Cons.Total assets (5-year summary)
Total liabilities¥6.5bnat 2023-06-30Cons.Liabilities
Total liabilities¥7.0bnat 2022-12-31Cons.Liabilities
Net assets / equity¥9.2bnat 2023-06-30Cons.Net assets
Net assets / equity¥8.0bnat 2022-12-31Cons.Net assets
Net assets / equity¥10.2bnat 2022-06-30Cons.Net assets (5-year summary)
Cash and deposits¥4.8bnat 2023-06-30Cons.Cash and deposits
Cash and deposits¥3.1bnat 2022-12-31Cons.Cash and deposits
Cash & equivalents¥4.5bnat 2023-06-30Cons.Cash and cash equivalents
Cash & equivalents¥2.8bnat 2022-12-31Cons.Cash and cash equivalents
Cash & equivalents¥4.4bnat 2022-06-30Cons.Cash and cash equivalents
Cash & equivalents¥5.5bnat 2021-12-31dCons.Cash and cash equivalents
Operating cash flow¥126m2023-01-01 → 2023-06-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥2.0bn2022-01-01 → 2022-12-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥631m2022-01-01 → 2022-06-30Cons.Net cash provided by used in operating activities
Investing cash flow¥707m2023-01-01 → 2023-06-30Cons.Net cash provided by used in investment activities
Investing cash flow¥190m2022-01-01 → 2022-12-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥96m2022-01-01 → 2022-06-30Cons.Net cash provided by used in investment activities
Financing cash flow¥827m2023-01-01 → 2023-06-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥997m2022-01-01 → 2022-12-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥501m2022-01-01 → 2022-06-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-11.362023-01-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-5.762023-04-01 → 2023-06-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-112.262022-01-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-64.172022-01-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-24.052022-04-01 → 2022-06-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio58.7%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio53.5%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio58.4%at 2022-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Otherother segmentsrevenue2023-01-01 → 2023-06-30¥2m
Otherother segmentsrevenue external2023-01-01 → 2023-06-30¥2m
Otherother segmentssegment profit2023-01-01 → 2023-06-30−¥11m
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-06-30−¥492m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥370m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥370m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentsegment profit2023-01-01 → 2023-06-30−¥407m
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥2.1bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥2.1bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2023-01-01 → 2023-06-30¥514m
Total Of Reportable Segments And Otherssegment totalrevenue2023-01-01 → 2023-06-30¥2.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-01-01 → 2023-06-30¥2.5bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-01-01 → 2023-06-30¥95m
Otherother segmentsrevenue2022-01-01 → 2022-06-30¥4m
Otherother segmentsrevenue external2022-01-01 → 2022-06-30¥4m
Otherother segmentssegment profit2022-01-01 → 2022-06-30−¥11m
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-06-30−¥645m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentrevenue2022-01-01 → 2022-06-30¥365m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentrevenue external2022-01-01 → 2022-06-30¥365m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentsegment profit2022-01-01 → 2022-06-30−¥1.6bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-06-30¥1.5bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-06-30¥1.5bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-06-30−¥117m
Total Of Reportable Segments And Otherssegment totalrevenue2022-01-01 → 2022-06-30¥1.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-01-01 → 2022-06-30¥1.9bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-01-01 → 2022-06-30−¥1.8bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 510
ItemContextValueUnit
Long term loans payablePrior1YearInstant2720000000JPY
Long term loans payableCurrentQuarterInstant2200000000JPY
Long term accounts payable otherPrior1YearInstant549000000JPY
Long term accounts payable otherCurrentQuarterInstant549000000JPY
Net defined benefit liabilityPrior1YearInstant659000000JPY
Net defined benefit liabilityCurrentQuarterInstant614000000JPY
Asset retirement obligations nclPrior1YearInstant133000000JPY
Asset retirement obligations nclCurrentQuarterInstant－JPY
Other nclPrior1YearInstant146000000JPY
Other nclCurrentQuarterInstant205000000JPY
Noncurrent liabilitiesPrior1YearInstant4208000000JPY
Noncurrent liabilitiesCurrentQuarterInstant3570000000JPY
LiabilitiesPrior1YearInstant7001000000JPY
LiabilitiesCurrentQuarterInstant6459000000JPY
Capital stockPrior1YearInstant1201000000JPY
Capital stockCurrentQuarterInstant1918000000JPY
Capital surplusPrior1YearInstant1642000000JPY
Capital surplusCurrentQuarterInstant2340000000JPY
Retained earningsPrior1YearInstant5239000000JPY
Retained earningsCurrentQuarterInstant4724000000JPY
Treasury stockPrior1YearInstant-348000000JPY
Treasury stockCurrentQuarterInstant-300000000JPY
Shareholders equityPrior1YearInstant7734000000JPY
Shareholders equityCurrentQuarterInstant8682000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant－JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant119000000JPY
Foreign currency translation adjustmentPrior1YearInstant309000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant370000000JPY
Valuation and translation adjustmentsPrior1YearInstant309000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant490000000JPY
Subscription rights to sharesPrior1YearInstant－JPY
Subscription rights to sharesCurrentQuarterInstant4000000JPY
Net assetsPrior1YearInstant8044000000JPY
Net assetsCurrentQuarterInstant9177000000JPY
Liabilities and net assetsPrior1YearInstant15046000000JPY
Liabilities and net assetsCurrentQuarterInstant15636000000JPY
Net salesPrior1YTDDuration1857000000JPY
Net salesCurrentYTDDuration2488000000JPY
Cost of salesPrior1YTDDuration2035000000JPY
Cost of salesCurrentYTDDuration1437000000JPY
Gross profitPrior1YTDDuration-177000000JPY
Gross profitCurrentYTDDuration1050000000JPY
Selling general and administrative expensesPrior1YTDDuration2240000000JPY
Selling general and administrative expensesCurrentYTDDuration1447000000JPY
Operating incomePrior1YTDDuration-2417000000JPY
Operating incomeCurrentYTDDuration-396000000JPY
Interest income noiPrior1YTDDuration1000000JPY
Interest income noiCurrentYTDDuration9000000JPY
Foreign exchange gains noiPrior1YTDDuration61000000JPY
Foreign exchange gains noiCurrentYTDDuration28000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-12-31pass rounding
balance sheet identityconsolidated 2023-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass